Big pharma companies partner to form AI-based start-up
Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on […]
Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on […]
Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a […]
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, […]
Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses Celebrating 20 years of […]
Shots: The collaboration will expand AstraZeneca’s portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is […]
Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, […]
Copyright © 2024 | WordPress Theme by MH Themes